Bausch Health Companies (NYSE:BHC) Lifted to "Buy" at StockNews.com

StockNews.com upgraded shares of Bausch Health Companies (NYSE:BHC - Free Report) from a hold rating to a buy rating in a research note issued to investors on Friday morning.

BHC has been the topic of a number of other reports. Truist Financial reduced their price target on shares of Bausch Health Companies from $8.00 to $7.00 and set a "hold" rating on the stock in a research report on Thursday, July 25th. Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. Jefferies Financial Group dropped their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, August 7th. Raymond James assumed coverage on shares of Bausch Health Companies in a research note on Wednesday, July 10th. They set a "market perform" rating and a $8.00 price objective on the stock. Finally, Royal Bank of Canada dropped their price objective on shares of Bausch Health Companies from $10.00 to $8.50 and set a "sector perform" rating on the stock in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.33.

Bausch Health Companies Stock Down 1.0 %

Shares of BHC traded down $0.08 during mid-day trading on Friday, hitting $8.04. The company had a trading volume of 609,607 shares, compared to its average volume of 2,940,944. The business's 50-day simple moving average is $7.22 and its 200-day simple moving average is $7.09. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The stock has a market cap of $2.90 billion, a PE ratio of -6.48 and a beta of 0.77.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. The firm had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.33 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. During the same period in the previous year, the company posted $0.81 earnings per share. On average, sell-side analysts expect that Bausch Health Companies will post 3.61 earnings per share for the current year.

Insider Buying and Selling

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the sale, the executive vice president now owns 435,198 shares in the company, valued at $2,702,579.58. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 8.12% of the company's stock.

Institutional Trading of Bausch Health Companies

Several institutional investors have recently added to or reduced their stakes in BHC. Headlands Technologies LLC bought a new stake in Bausch Health Companies during the second quarter valued at $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies during the second quarter valued at $71,000. Certuity LLC acquired a new position in shares of Bausch Health Companies during the second quarter valued at $75,000. Bfsg LLC boosted its holdings in shares of Bausch Health Companies by 46.7% during the second quarter. Bfsg LLC now owns 11,450 shares of the company's stock valued at $80,000 after acquiring an additional 3,643 shares during the period. Finally, Kendall Capital Management acquired a new position in shares of Bausch Health Companies during the second quarter valued at $87,000. Institutional investors own 78.65% of the company's stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.